Minocycline Doesn't Slow Geographic Atrophy in AMD Minocycline Doesn't Slow Geographic Atrophy in AMD
A potential drug for age-related macular degeneration failed to slow geographic atrophy, according to data from a long-term study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 27, 2023 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
As expected, significantly lower demand for COVID-19 tests leads to a decrease inGroup sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Divisionsales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, whiledivisional salesare 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022Highlights in the first quarter:US approval of  Polivy (first-line treatment for an aggressive form of blood cancer)EU approva...
Source: Roche Investor Update - April 26, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
Basel, 26 April 2023As expected, significantly lower demand for COVID-19 tests leads to a decrease inGroup sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Divisionsales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, whiledivisional salesare 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022Highlights in the first quarter:US approval of  Polivy (first-line treatment for an aggressive form of blo...
Source: Roche Media News - April 26, 2023 Category: Pharmaceuticals Source Type: news

New Vabysmo data suggest greater retinal drying versus aflibercept in nAMD and DME
Post-hoc analyses from four phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME)More Vabysmo patients with nAMD had absence of retinal fluid at 12 weeks in a post-hoc analysis from the phase III TENAYA and LUCERNE studiesDME patients treated with Vabysmo had less blood vessel leakage in the macula at 16 weeks in a post-hoc analysis from the phase III YOSEMITE and RHINE studiesBasel, 25 April 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that post-hoc data indicate treatment with Va...
Source: Roche Investor Update - April 25, 2023 Category: Pharmaceuticals Source Type: news

New Vabysmo data suggest greater retinal drying versus aflibercept in nAMD and DME
Post-hoc analyses from four phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME)More Vabysmo patients with nAMD had absence of retinal fluid at 12 weeks in a post-hoc analysis from the phase III TENAYA and LUCERNE studiesDME patients treated with Vabysmo had less blood vessel leakage in the macula at 16 weeks in a post-hoc analysis from the phase III YOSEMITE and RHINE studiesBasel, 25 April 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that post-hoc data indicate treatment with Va...
Source: Roche Media News - April 25, 2023 Category: Pharmaceuticals Source Type: news

Have scientists found a way to reverse sight loss? A jab of skin cells could hold the key
An estimated 250,000 people in the UK live with severe visual problems due to dry age-related macular degeneration (AMD) and there is no treatment. (Source: the Mail online | Health)
Source: the Mail online | Health - April 24, 2023 Category: Consumer Health News Source Type: news

New jab offers hope to 500,000 Britons suffering dry age-related macular degeneration
Pegcetacoplan tackles dry age-related macular degeneration, or dry AMD, which affects more than 500,000 Britons and causes a quarter of severe sight- loss cases in the UK. (Source: the Mail online | Health)
Source: the Mail online | Health - April 22, 2023 Category: Consumer Health News Source Type: news

Janssen to Highlight Innovation in Retinal Pipeline at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
Click to Access Audio Press ReleaseRARITAN, N.J., April 21, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that five company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting in New Orleans from April 23-27, 2023. Janssen presentations will include updates from the Phase 1/2 MGT009 trial for investigational gene therapy botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) in patients with the inherited retinal disease (IRD) X-linked retinitis pigmentosa (XLRP) associated with the retinitis pigmentos...
Source: Johnson and Johnson - April 21, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news

Roche data highlights strength of ophthalmology portfolio and commitment to advancing eye care at ARVO 2023
Vabysmo data suggest rapid and robust drying of retinal fluid in patients withneovascular or ‘wet’ age-related macular degeneration and diabetic macular edemaReal-world studies ofVabysmo demonstrate ability to extend treatment intervals in the first four months while maintaining visual acuityClinical data on an investigational anti-interleukin-6 treatment inuveitic macular edema will be presented for the first timeBasel, 13 April 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data for its approved and investigational medicines will be highlighted in 30 abstracts at the 2023 Association for Research ...
Source: Roche Media News - April 13, 2023 Category: Pharmaceuticals Source Type: news

Roche data highlights strength of ophthalmology portfolio and commitment to advancing eye care at ARVO 2023
Vabysmo data suggest rapid and robust drying of retinal fluid in patients withneovascular or ‘wet’ age-related macular degeneration and diabetic macular edemaReal-world studies ofVabysmo demonstrate ability to extend treatment intervals in the first four months while maintaining visual acuityClinical data on an investigational anti-interleukin-6 treatment inuveitic macular edema will be presented for the first timeBasel, 13 April 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data for its approved and investigational medicines will be highlighted in 30 abstracts at the 2023 Association for Research ...
Source: Roche Investor Update - April 13, 2023 Category: Pharmaceuticals Source Type: news

Healthy Eating Habits for Age-Related Macular Degeneration
If you have age-related macular degeneration (AMD), healthy foods may slow vision loss related to the disease. Learn more about which foods are best for AMD. (Source: WebMD Health)
Source: WebMD Health - April 8, 2023 Category: Consumer Health News Source Type: news

Extremely rare gene variants point to a potential cause of age-related macular degeneration
Membrane attack complex is a potential therapeutic target to slow or prevent the development of AMD. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - April 3, 2023 Category: American Health Source Type: news

Depression and Age-Related Macular Degeneration
Margret Krakauer shares how the diagnosis affected her mental health and how she overcame it. (Source: WebMD Health)
Source: WebMD Health - March 31, 2023 Category: Consumer Health News Source Type: news

World's leading cause of blindness could be treated with a new fish oil pill, study claims
A fish oil supplement containing an omega-3 fatty acid may hold the key to treating some of the world's leading causes of blindness including diabetes and age-related macular degeneration. (Source: the Mail online | Health)
Source: the Mail online | Health - March 27, 2023 Category: Consumer Health News Source Type: news

Two supplements that can prevent advanced age-related macular degeneration by 25 percent
They contain a mix of various "powerful" antioxidants known to protect against vision loss. (Source: Daily Express - Health)
Source: Daily Express - Health - March 21, 2023 Category: Consumer Health News Source Type: news